Susquehanna Fundamental Investments, LLC Corcept Therapeutics Inc Transaction History

Susquehanna Fundamental Investments, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 07, 2024	BUY	$21.1 - $27.46 $311,014 - $404,760	14,740 New	14,740 $371 Million
Q4 2021 Feb 14, 2022	SELL	$17.1 - $23.34 $895,851 - $1.22 Million	-52,389 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$19.68 - $22.53 $574,439 - $657,628	29,189 Added 125.81%	52,389 $1.03 Million
Q2 2021 Aug 11, 2021	SELL	$19.97 - $24.43 $412,420 - $504,528	-20,652 Reduced 47.09%	23,200 $510,000
Q1 2021 May 17, 2021	BUY	$23.49 - $30.56 $11,157 - $14,516	475 Added 1.1%	43,852 $1.04 Million
Q4 2020 Feb 16, 2021	BUY	$16.78 - $27.3 $311,722 - $507,152	18,577 Added 74.91%	43,377 $1.14 Million
Q3 2020 Nov 16, 2020	BUY	$12.46 - $19.98 $309,008 - $495,504	24,800 New	24,800 $432,000

311

88.3M

1.07M

973K

Ticker CORT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,105,000
Market Cap $4.87B
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.